Europe
It took more than 8 months and a series of sweetened offers, but Sanofi was able to close their $11.6B deal to buy Bioverativ without triggering an auction.
Syndesi will work to modulate the synaptic vesicle protein SV2A.
The plan is an effort to ward off pressure to break up the firm by activist investor Elliott Advisors.
The company eleased the pipeline update at its Q4 earnings report.
Koss said affected employees will receive severance benefits and career guidance.
Since Emma Walmsley took over leadership at Glaxo, expectations have been both high and hypercritical.
Bexsero is the first vaccine in the world to receive the designation twice.
After yesterday’s big plunge in the stock market, and today with the Dow Jones Industrial Average dropping more than 500 points after opening, but mostly recovering, volatility appears to be the key word to describe the stock market.
The company says the vaccine takes a novel approach.
According to sources reported by Reuters, potential buyers have been winnowed down to two pharma companies, three private equity funds, and a consortium of buyers.
PRESS RELEASES